However, unlike doxorubicin, R2016 was observed to induce the late stage apoptosis (Annexin V+/PI+) in both the lung cancer (LLC, Fig 3A) and melanoma (B16F10, Fig 3B) cells in a dose-dependent manner. Here, ANXA5 is linked to lung cancer.